中国生物制药(01177.HK)：TRD221“补体蛋白调节剂”临床试验申请获NMPA批准

Core Viewpoint - China National Pharmaceutical Group (01177.HK) announced that its subsidiary Beijing Tide Pharmaceutical Co., Ltd. has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative drug TRD221, a complement protein modulator intended for the treatment of osteoarthritis [1]. Group 1 - The drug TRD221 is classified as a national Class 1 innovative drug [1]. - The approval from NMPA marks a significant milestone for the company in its drug development pipeline [1]. - The intended use of TRD221 is specifically for osteoarthritis, indicating a focus on addressing this prevalent condition [1].